An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in SchizophreniaKotaro Sakamoto, Yukio Ago, Daichi Koan et al.|Biological and Pharmaceutical Bulletin|2026Cited by 0